Investor Scrutiny

Question

The deck cites the UK CMA investigation to support the problem of information asymmetry in vet care. But where is the company's own evidence that pet owners want Bevetu specifically? How many user interviews were done? How many owners would actually pay £3/month for this?

Current answer

The deck shows that the market has a problem, but it does not prove demand for this product. The CMA report is valid context, but not product validation.

What would count as a real answer

• 30–50 user interviews
• waitlist or landing page conversion data
• pricing tests
• early paid pilots

Question

Why is this not just a form plus ChatGPT? A prototype seems easy to build. What is the actual moat?

Current answer

The deck argues that the long-term moat is Anibrary, a vet-validated dataset. The near-term differentiation is structured intake, vet-designed flows, and a clinic-oriented report.

Why it matters

The workflow may be useful, but the technical stack as presented is not strongly defensible. The moat is deferred to a future dataset that does not exist yet.

What would count as a real answer

• a credible cold-start dataset plan
• evidence that the workflow outperforms free substitutes
• proof that data quality compounds over time

Question

The whole product flow assumes vets will review the report, agree with it, or explain why they disagree. But what evidence is there that vets want this? Wouldn't many vets see it as extra work or a challenge to their judgment?

Current answer

There is no validation in the deck that vets will accept this workflow. It is presented as an assumption.

Why it matters

If vets ignore the report, the owner-facing value drops sharply and the clinic-side feedback loop weakens. This is not a minor issue — it is structural to the current model.

What would count as a real answer

• vet interviews
• design partners
• pilot clinics
• LOIs or workflow testing

Question

The deck presents Anibrary as the defensible asset. But the dataset requires user-submitted outcomes, vet validation, and scale. None of that exists yet. Isn't this just a future promise?

Current answer

Yes — today, Anibrary is more a strategic intention than an actual moat.

Why it matters

The pitch currently depends on a circular logic: users create data, data improves accuracy, accuracy attracts users. Without a seed strategy, this is a classic cold-start problem.

What would count as a real answer

• seeded cases from vet partners or schools
• licensed or public data sources
• retrospective anonymized case contributions
• a narrow-condition launch with expert-reviewed cases

Question

Why would a user pay for Bevetu when ChatGPT is free and already on their phone? Isn't ChatGPT a substitute?

Current answer

The beginning of an answer exists: Bevetu is not trying to beat LLMs on raw intelligence, but on structured workflow, guided questioning, and trust design.

Why it matters

This is a positioning answer, not a durable defensibility answer. The follow-up will always be: "Why can't ChatGPT add this flow?"

What would count as a real answer

• proof the structured workflow materially improves behavior or outcomes
• trust or compliance advantage
• proprietary data or integrations that general tools lack

Question

The CMA found structural issues in the veterinary market: consolidation, pricing opacity, prescribing conflicts. Bevetu gives owners a better pre-visit assessment. Does it actually solve the problem you are citing?

Current answer

The product does not solve the structural economics of the vet market. It addresses an owner-level symptom: poor preparation and low confidence before treatment discussions.

Why it matters

Better framing: "We are not fixing the veterinary market structure. We are helping owners navigate it better."

Question

The deck uses dog and cat population to build TAM, SAM, and SOM, then assumes 3% of SAM after five years. Why is 3% credible? And should TAM be pets or owners?

Current answer

The market sizing is directionally illustrative, but not deeply grounded. The assumptions appear chosen to support a respectable forecast rather than derived from evidence.

What would count as a real answer

• owner-based segmentation
• usage frequency data
• channel-specific acquisition math
• bottom-up market sizing from real customer behavior

Question

The model assumes £3/month, 25% paid conversion, and £11 per report for data licensing. But where are CAC, churn, LTV, payback, and buyer use cases?

Current answer

The revenue model is a set of assumptions, not a fully defensible operating model.

Why it matters

For a consumer subscription, churn and acquisition matter more than headline market size. For data licensing, buyer identity and data quality matter more than theoretical price per report.

What would count as a real answer

• scenario-based model
• sensitivity analysis
• early acquisition test results
• identified B2B buyers and use cases

Question

This is medical-adjacent guidance involving animals. What happens if an owner delays care based on the assessment? What are the legal, insurance, and regulatory implications?

Current answer

The deck does not adequately address regulation, professional boundaries, or liability.

Why it matters

This is existential, not cosmetic. The product sits close to clinical judgment and could face questions around claims, disclaimers, liability coverage, and acceptability within veterinary practice norms.

What would count as a real answer

• legal review
• clear product boundary definition
• insurance plan
• documented compliance approach

Question

The team appears strong on software and product, but veterinary expertise is advisory, not full-time. Is that enough for a clinically sensitive workflow?

Current answer

The team is credible on product and execution, but there is no full-time veterinary operator in the core team.

What would count as a real answer

• a more engaged veterinary lead
• clinical advisory depth
• formal partnerships with vets or vet institutions

Question

The deck cites SEIS/EIS approval, Azure credits, incubator programs, and support services. But where are users, revenue, pilots, or LOIs?

Current answer

The traction shown is ecosystem validation, not market traction.

Why it matters

These signals help credibility, but they do not prove demand.

Question

The ask is £250K for 10% equity, implying a £2.5M post-money valuation, pre-launch and pre-revenue. Why is that justified?

Current answer

The deck does not provide enough evidence to strongly justify that price today.

What would count as a real answer

• real user evidence
• pilots
• stronger moat evidence
• narrower claims and a more credible de-risking path